Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Blueprint Medicines Corp shares valued at $511,400 were sold by Albers Jeffrey W. on Jan 13 ’25. At $102.28 per share, Albers Jeffrey W. sold 5,000 shares. The insider’s holdings dropped to 157,557 shares worth approximately $16.38 million following the completion of this transaction.
Also, Hurley Ariel sold 2,250 shares, netting a total of over 225,000 in proceeds. Following the sale of shares at $100.00 each, the insider now holds 14,967 shares.
Before that, Albers Jeffrey W. had added 5,000 shares to its account. In a trade valued at $511,398, the Director bought Blueprint Medicines Corp shares for $102.28 each.
As published in their initiating research note from JP Morgan on November 14, 2024, Blueprint Medicines Corp [BPMC] has been an Overweight and the price target has been revised to $126. Analysts at UBS started covering the stock with ‘”a Neutral”‘ outlook in a report released in late October. As of May 14, 2024, Stephens has initiated its “an Overweight” rating for BPMC. Earlier on May 06, 2024, Leerink Partners upgraded its rating. Their new recommendation was “a Market perform” for BPMC stock which previously was a “an Underperform”.
Analyzing BPMC Stock Performance
During the last five days, there has been a surge of approximately 14.70%. Over the course of the year, Blueprint Medicines Corp shares have jumped approximately 19.18%. Shares of the company reached a 52-week high of $107.88 on 01/15/25 and a 52-week low of $86.72 on 01/10/25. A 50-day SMA is recorded $94.44, while a 200-day SMA reached $96.91. Nevertheless, trading volume fell to 0.8 million shares from 1.11 million shares the previous day.
Support And Resistance Levels for Blueprint Medicines Corp (BPMC)
According to the 24-hour chart, there is a support level at 102.92, which, if violated, would cause prices to drop to 101.88. In the upper region, resistance lies at 105.74. The next price resistance is at 107.52. RSI (Relative Strength Index) is 64.33 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at 10.42, which suggests the price will increase in the coming days. Percent R is at 17.89%, indicating bullish price movement. Stochastics %K at selling indicates that the stock is to be held.
